Despite its significance, PD-L1 as a biomarker has limitations. The heterogeneity of PD-L1 expression within tumors and between different biopsy samples can lead to variability in test results. Additionally, PD-L1 expression alone may not fully predict the response to immunotherapy, as other factors in the tumor microenvironment and the immune system also play a role.
